Drug targeting to specific vascular sites

Drug Discovery Today

Volumn 7, Issue 22, 2002, Pages 1138-1143

  Ruoslahti, Erkki ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPEPTIDASE P; ANGIOGENESIS INHIBITOR; ARGINYLGLYCYLASPARTIC ACID; CELL SURFACE PROTEIN; CYSTEINYLCYSTEINYLASPARAGINYLGLYCYLARGINYLCYSTEINE; DOXORUBICIN; LIPID; MOLECULAR MARKER; MONOCLONAL ANTIBODY; PEPTIDASE; PEPTIDE DERIVATIVE; PEPTIDE LIBRARY; PROTEINASE; PROTEOGLYCAN; SERYLMETHIONYLSERYLISOLEUCYLALANYLARGINYLLEUCINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANGIOGENESIS; ANTIBODY LIBRARY; ATHEROSCLEROTIC PLAQUE; BACTERIOPHAGE; BLOOD VESSEL; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER THERAPY; CARDIOTOXICITY; CELL ADHESION; CELL MIGRATION; CELLULAR DISTRIBUTION; COLON CANCER; DRUG TARGETING; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; INFLAMMATION; LIVER TOXICITY; LUNG BLOOD VESSEL; LYMPH VESSEL; MAMMARY GLAND; MOUSE; NONHUMAN; PHAGE DISPLAY; REVIEW; TUMOR GROWTH; TUMOR VASCULARIZATION; VIRAL GENE THERAPY;

ANIMALS; BIOLOGICAL MARKERS; DRUG DELIVERY SYSTEMS; HUMANS; LYMPHATIC SYSTEM; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0037112310     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(02)02501-1     Document Type: Review

References (39)

1. Ruoslahti E., Rajotte D. An address system in the vasculature of normal tissues and tumors. Annu. Rev. Immunol. 18:2000;813-827.
2. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353-364.
3. Jacobson B.S., et al. Identification of endothelial cell-surface proteins as targets for diagnosis and treatment of disease. Nat. Med. 2:1996;482-484.
4. Elble R.C., et al. Molecular and functional characterization of a murine calcium-activated chloride channel expressed in smooth muscle. J. Biol. Chem. 277:2002;18586-18591.
5. Ruoslahti E. Specialization of tumour vasculature. Nat. Rev. Cancer. 2:2002;83-90.
6. Gerlag D.M., et al. Suppression of murine collagen-induced arthritis by targeted apoptosis of synovial neovasculature. Arthritis Res. 3:2001;357-361.
7. Houston P., et al. Homing markers for atherosclerosis: applications for drug delivery, gene delivery and vascular imaging. FEBS Lett. 492:2001;73-77.
8. Abdel-Ghany M., et al. Truncated dipeptidyl peptidase IV is a potent anti-adhesion and anti-metastasis peptide for rat breast cancer cells. Invasion Metastasis. 18:1998;35-43.
9. Essler M., Ruoslahti E. Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature. Proc. Natl. Acad. Sci. U. S. A. 99:2002;2252-2257.
10. Pasqualini R., et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 60:2000;722-727.
11. Eliceiri B.P., Cheresh D.A. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J. Clin. Invest. 103:1999;1227-1230.
12. Kim S., et al. A regulation of angiogenesis in vivo by ligation of integrin α5β1 with the central cell-binding domain of fibronectin. Am. J. Pathol. 156:2000;1345-1362.
13. Arap W., et al. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 279:1998;377-380.
14. St Croix B., et al. Genes expressed in human tumor endothelium. Science. 289:2000;1197-1202.
15. Christian S., et al. Molecular cloning and characterization of EndoGlyx-1, an EMILIN-like multisubunit glycoprotein of vascular endothelium. J. Biol. Chem. 276:2001;48588-48595.
16. Hu Z., Garen A. Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 98:2001;12180-12185.
17. Ozerdem U., et al. NG2 proteoglycan is expressed exclusively by mural cells during vascular morphogenesis. Dev. Dyn. 222:2001;218-227.
18. Halin C., et al. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat. Biotechnol. 20:2002;264-269.
19. Alitalo K., Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cells. 1:2002;219-227.
20. Laakkonen P., et al. Tumor-homing peptide with a lymphatic vessel-related targeting specificity. Nat. Med. 8:2002;751-755.
21. Chang Y.S., et al. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc. Natl. Acad. Sci. U. S. A. 97:2000;14608-14613.
22. Folberg R., et al. Vasculogenic mimicry and tumor angiogenesis. Am. J. Pathol. 156:2000;361-381.
23. Yang J.T., et al. Embryonic mesodermal defects in alpha 5 integrin-deficient mice. Development. 119:1993;1093-1105.
24. Bader B.L., et al. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell. 95:1998;507-519.
25. Reynolds L.E., et al. Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins. Nat. Med. 8:2002;27-34.
26. Curnis F., et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res. 62:2002;867-874.
27. Kerbel R.S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays. 13:1991;31-36.
28. Olson T.A., et al. Targeting the tumor vasculature: inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate. Int. J. Cancer. 73:1997;865-870.
29. Assa-Munt N., et al. Solution structures and integrin binding activities of an RGD peptide with two isomers. Biochemistry. 40:2001;2373-2378.
30. Browder T., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60:2000;1878-1886.
31. Ellerby H.M., et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat. Med. 5:1999;1032-1038.
32. Arap W., et al. Targeting the prostate vasculature for destruction through a vascular address. Proc. Natl. Acad. Sci. U. S. A. 99:2002;1527-1531.
33. Porkka K., et al. Targeting of peptides to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc. Natl. Acad. Sci. U. S. A. 99:2002;7444-7449.
34. Wickham T.J. Targeting adenovirus. Gene Ther. 7:2000;110-114.
35. Haviv Y.S., et al. Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res. 62:2002;4273-4281.
36. Hood J.D., et al. Tumor regression by targeted gene delivery to the neovasculature. Science. 296:2002;2404-2407.
37. Xu J., et al. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J. Cell Biol. 154:2001;1069-1080.
38. Huang X., et al. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science. 275:1997;547-550.
39. Rajotte D., Ruoslahti E. Membrane dipeptidase is the receptor for a lung-targeting peptide identified by in vivo phage display. J. Biol. Chem. 274:1999;11593-11598.